Investors

Cadrenal Therapeutics is focused on developing tecarfarin, a novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is Phase-3 ready and has been evaluated in eleven (11) human clinical trials and over 1,003 individuals.

Our mission is to build a company with a foundation of product candidates that significantly improve quality of life and patient outcomes for individuals with cardiorenal diseases.